3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
5
Withdrawn
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
241
Radiotherapy
217
Gemcitabine
187
Cisplatin
185
Carboplatin
182
Docetaxel
166
Bevacizumab
166
Paclitaxel
144
Capecitabine
142
Rituximab
141
pembrolizumab
140
Nivolumab
126
Oxaliplatin
124
Dexamethasone
122
Fluorouracil
113
fludarabine
104
Radiosurgery
101
Doxorubicin
99
fludarabine phosphate
97
Irinotecan
96
Etoposide
95
Lenalidomide
93
Cytarabine
92
Magnetic Resonance Spectroscopy
90
Radiation
89
Filgrastim
89
Leucovorin
88
Bortezomib
86
Cetuximab
80
Pemetrexed
79
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
OTHER
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled